Adult Hemoglobinopathy Testing Market by Group (Structural Hemoglobin Variants, Thalassemia Syndromes), Type (Hb Electrophoresis, HPLC Detection, Mass Spectrometry), End-Use - Global Forecast 2024-2030

Adult Hemoglobinopathy Testing Market by Group (Structural Hemoglobin Variants, Thalassemia Syndromes), Type (Hb Electrophoresis, HPLC Detection, Mass Spectrometry), End-Use - Global Forecast 2024-2030


The Adult Hemoglobinopathy Testing Market size was estimated at USD 4.72 billion in 2023 and expected to reach USD 5.10 billion in 2024, at a CAGR 6.17% to reach USD 7.18 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Adult Hemoglobinopathy Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Adult Hemoglobinopathy Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Adult Hemoglobinopathy Testing Market, highlighting leading vendors and their innovative profiles. These include ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Bio-Rad Laboratories, Inc., Bluebird Bio, Inc., Creative Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA Group, Illumina, Inc., Laboratory Corporation of America Holdings, Merck KGaA, PerkinElmer, Inc., Quest Diagnostics Incorporated, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers AG, Sysmex Europe SE, Thermo Fisher Scientific Inc., Tosoh Corporation, and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Adult Hemoglobinopathy Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Group

Structural Hemoglobin Variants
  • Thalassemia Syndromes
  • Type

    Hb Electrophoresis
  • HPLC Detection
  • Mass Spectrometry
  • End-Use

    Hospital
  • Laboratories
  • Medical & Research Institute
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Adult Hemoglobinopathy Testing Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Adult Hemoglobinopathy Testing Market?
    3. What are the technology trends and regulatory frameworks in the Adult Hemoglobinopathy Testing Market?
    4. What is the market share of the leading vendors in the Adult Hemoglobinopathy Testing Market?
    5. Which modes and strategic moves are suitable for entering the Adult Hemoglobinopathy Testing Market?


    Note: PDF & Excel + Online Access - 1 Year

  • 1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Adult Hemoglobinopathy Testing Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Prevalence of thalassemia and sickle cell disease (SCD) worldwide
    5.1.1.2. Inclination toward early diagnosis and treatment of diseases
    5.1.1.3. Ongoing newborn screening programs and need for accurate and reliable testing methodologies
    5.1.2. Restraints
    5.1.2.1. High cost associated with adult-hemoglobinopathy-testing
    5.1.3. Opportunities
    5.1.3.1. Technological advancements in adult-hemoglobinopathy-testing methods
    5.1.3.2. Ongoing research and development on adult-hemoglobinopathy
    5.1.4. Challenges
    5.1.4.1. Technical limitations in devices used for adult-hemoglobinopathy-testing
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Adult Hemoglobinopathy Testing Market, by Group
    6.1. Introduction
    6.2. Structural Hemoglobin Variants
    6.3. Thalassemia Syndromes
    7. Adult Hemoglobinopathy Testing Market, by Type
    7.1. Introduction
    7.2. Hb Electrophoresis
    7.3. HPLC Detection
    7.4. Mass Spectrometry
    8. Adult Hemoglobinopathy Testing Market, by End-Use
    8.1. Introduction
    8.2. Hospital
    8.3. Laboratories
    8.4. Medical & Research Institute
    9. Americas Adult Hemoglobinopathy Testing Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Adult Hemoglobinopathy Testing Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Adult Hemoglobinopathy Testing Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. ARKRAY, Inc.
    13.1.2. Beckman Coulter, Inc. by Danaher Corporation
    13.1.3. Bio-Rad Laboratories, Inc.
    13.1.4. Bluebird Bio, Inc.
    13.1.5. Creative Diagnostics
    13.1.6. F. Hoffmann-La Roche Ltd.
    13.1.7. HORIBA Group
    13.1.8. Illumina, Inc.
    13.1.9. Laboratory Corporation of America Holdings
    13.1.10. Merck KGaA
    13.1.11. PerkinElmer, Inc.
    13.1.12. Quest Diagnostics Incorporated
    13.1.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    13.1.14. Shimadzu Corporation
    13.1.15. Siemens Healthineers AG
    13.1.16. Sysmex Europe SE
    13.1.17. Thermo Fisher Scientific Inc.
    13.1.18. Tosoh Corporation
    13.1.19. Trinity Biotech PLC
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ADULT HEMOGLOBINOPATHY TESTING MARKET RESEARCH PROCESS
    FIGURE 2. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2023 VS 2030
    FIGURE 3. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ADULT HEMOGLOBINOPATHY TESTING MARKET DYNAMICS
    FIGURE 7. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2030 (%)
    FIGURE 8. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
    FIGURE 10. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
    FIGURE 12. ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADULT HEMOGLOBINOPATHY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ADULT HEMOGLOBINOPATHY TESTING MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ADULT HEMOGLOBINOPATHY TESTING MARKET SHARE, BY KEY PLAYER, 2023

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings